Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

By sjmartinez • September 29, 2024

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587. Epub ahead of print. PMID: 39342463.

Tags: CDK, CDK inhibition, cyclin‐dependent kinase, dinaciclib, Hematology/Oncology, melanoma, Publications

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

Brady MR, Matulionis N, Christofk HR, Garon EB, Lisberg A, Shackelford DB, Momcilovic M. Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous[...]

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry

Daskou M, Zaiss AK, Jeyachandran AV, Takano KA, Kan RL, Paravastu R, Gerald E, Satheeshkumar N, Rios-Rodriguez J, Russell B, Brault AC, Bhaduri A, Garcia[...]